Survival impact of prophylactic cranial irradiation in small-cell lung cancer in the modern era of magnetic resonance imaging staging

Table 2 Clinical and treatment-related characteristics of patients with limited-stage who had no brain metastases at baseline

Variables	Number of patients (%)		P
Variables	PCI (n = 26)	No PCI (n = 81)	P
Age (year)
Median (range)	60 (43‒76)	69 (44‒82)	0.001
Gender
Male	22 (85)	69 (85)	1.000
Female	4 (15)	12 (15)	1.000
ECOG performance score^a
0‒1	21 (81)	55 (68)	1.000
≥ 2	3 (12)	8 (10)	1.000
Ever-smoker^a
No	1 (4)	9 (11)	0.445
Yes	25 (96)	70 (86)	0.445
Body mass index (kg/m²)
Median (range)	24.1 (15.8‒29.4)	23.8 (15.4‒32.7)	0.776
No. of symptoms at diagnosis
Median (range)	2 (0‒3)	1 (0‒4)	0.608
Clinical T stage^a
T1‒2	13 (56)	31 (50)	0.593
T3‒4	10 (44)	31 (50)	0.593
Clinical N stage^a
N0‒1	2 (8)	18 (22)	0.147
N2‒3	23 (92)	62 (78)	0.147
Definitive treatment
Chemoradiotherapy^b	19 (73)	38 (47)	0.055
Chemotherapy	6 (23)	31 (38)
Others^c	1 (4)	12 (15)
Chemotherapy regimens
Cisplatin-based doublet	19 (73)	48 (68)	0.551
Carboplatin-based doublet	6 (23)	20 (28)
Others	1 (4)	3 (4)
Cycles of first-line chemotherapy
< 4	1 (4)	27 (38)	0.001
≥ 4	25 (96)	44 (62)	0.001
Salvage treatment
Chemoradiotherapy^b	5 (19)	10 (12)	0.676
Chemotherapy	5 (19)	11 (14)
Others^c	2 (8)	8 (10)
No treatment	14 (54)	52 (64)

^aMissing values were excluded
^bCases with concurrent or sequential chemoradiotherapy were included
^cPatients who received radiotherapy alone or surgery (± adjuvant therapy) were included
PCI, prophylactic cranial irradiation; ECOG, Eastern Cooperative Oncology Group

ISSN: 1748-717X